GSK said it plans five phase 3 studies for an antibody-drug conjugate licensed from Hansoh Pharma after early promising data. The company’s move expands the late-stage footprint for a gynecologic cancer ADC and signals an intent to pursue broader registration-style evidence. The announcement follows an ADC arms race in oncology, where evidence depth across tumor settings and regimen optimization is often necessary to secure label positioning. GSK’s phase 3 plan will be watched for trial design, patient selection, and how endpoints align with regulatory expectations. For Hansoh and GSK, the step deepens their licensing-driven pipeline strategy in ADCs and increases competition in women’s cancers.